Dr Rivera-Ortega a Respiratory Consultant specialising in interstitial lung diseases (ILD), and has been working in the ILD unit of Wythenshawe Hospital since April 2018, for Manchester University NHS Foundation Trust.
She has been involved in research activities for over 15 years, and has been the Principal Investigator in multiple clinical studies and trials - both commercial and non-commercial. Her areas of expertise include IPF, familial ILD, telomere biology disorders , post-COVID-19 ILD, and the development of a rapid circuit for early ILD assessment.
Dr Rivera-Ortega’s appointment makes her the 6th member of the board, which was formed in August 2022 to bring together leading experts in the field of clinical trials and drug development. The board members are responsible for advising and supporting Qureight’s work to accelerate lung disease clinical trials and to develop new and clearer clinical endpoints.
Dr Rivera-Ortega says: As a board member, I look forward to contributing to the optimisation of Qureight’s trial development strategy, thereby achieving better outcomes for IPF patients. What I am most excited about is collaborating with other board members to improve the efficiency and accuracy of clinical data management, which will ultimately benefit ILD patients.
Dr Muhunthan Thillai, co-founder and CEO of Qureight, says: Dr Rivera-Ortega has a proven track record in the management of complex patients with progressive lung diseases and significant expertise working in clinical trials. Her addition to our Scientific Advisory Board advances our global expertise in complex lung data analytics.